Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Fresenius signs exclusive development deal with WuXi Biologics to expand biosimilars pipeline

By Public Technologies
  • Fresenius entered an exclusive development agreement with WuXi Biologics, securing options for up to 37 biosimilar candidates over the next decade.
  • The deal could expand its marketed and pipeline portfolio from 29 to 66 molecules, targeting over €370 billion in originator sales.
  • Selected programs will use fee-for-service payments, with Fresenius retaining exclusive global commercialization rights and full product economics.
  • Manufacturing strategy remains under its control, including potential transfers of selected products to wholly owned mAbxience.
  • Operating cash flow will fund the agreement without new financing; 2026 guidance and the existing 2030 Biopharma ambition remain unchanged.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2426078_en) on November 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.